How Mouse Models Pave the Way to Precision Cancer Medicine

The AACR is holding a special conference, Advances in Modeling Cancer in Mice: Technology, Biology, and Beyond, in Orlando, Florida, September 24-27. This conference will highlight recent advances in the design and implementation of genetically engineered mouse models of cancer.

Read More

AACR Cancer Progress Report 2017: Harnessing Research Discoveries to Save Lives

Today, the American Association for Cancer Research (AACR) released its seventh annual Cancer Progress Report. The report highlights how federally funded research that provides a deep understanding of the biology of cancer is spurring advances across the clinical cancer care continuum that are improving survival and quality of life for people around the world.

Read More

New Treatment for Adults with Acute Lymphoblastic Leukemia Approved by the FDA

This week’s excitement surrounding the groundbreaking U.S. Food and Drug Administration (FDA) approval of the CAR T–cell therapy tisagenlecleucel (Kymriah) for treating certain pediatric and young adult patients with acute lymphoblastic leukemia (ALL) was not the only good news for ALL community in August. Earlier in the month, the FDA approved a new molecularly targeted therapeutic called inotuzumab ozogamicin (Besponsa) for treating adults who have B-cell precursor ALL that did not respond to initial treatment or that returned after treatment.

Read More

Lessons Learned From Combining Anti-OX40 and Anti-PD1 Immunotherapies

A pair of studies published recently in journals of the American Association for Cancer Research bring to our attention the unexpected negative consequences of combining two immunotherapeutics concurrently, and discuss the mechanisms behind improved antitumor effects and survival outcomes with sequential administration of the two drugs.

Read More

FDA Approves Two New Treatments for Acute Myeloid Leukemia

This week, the U.S. Food and Drug Administration (FDA) added two new treatments to the armamentarium for hematologic oncologists treating certain groups of patients with acute myeloid leukemia (AML): enasidenib (Idhifa) and Vyxeos. This news is particularly welcome because AML is the form of leukemia with the lowest five-year relative survival rate.

Read More

Charting the Future of Cancer Health Disparities Research

Yesterday, the American Association for Cancer Research (AACR) joined the American Cancer Society (ACS), the American Society of Clinical Oncology (ASCO), and the National Cancer Institute (NCI) in releasing a joint position statement to guide the future of cancer health disparities research.

Read More

AACR Blog Turns 3: Check Out Our Top 10 Posts

Three years ago, the American Association for Cancer Research (AACR) launched this blog with a welcome post from Chief Executive Officer Margaret Foti, PhD, MD (hc). Since then, we’ve had the privilege of reporting on some significant progress against cancer, including the rise of immunotherapy and precision medicine.

Read More

FDA Approves New Lung Cancer Treatment and First Next-Gen Companion Diagnostic

Hot on the heels of the FDA’s landmark approval of an anticancer therapeutic for use based on whether a patient has a tumor with certain biomarkers, rather than a tumor originating at a certain anatomic site, the agency approved the first companion diagnostic that can detect mutations in multiple genes in a single test.

Read More